TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, different signalling pathways, such as the β-catenin [12] MYC and p53 pathways [13], have been shown to be unaffected by TKI treatment but are deregulated in CML LSC compared with their healthy HSC counterparts.